NEPHRO CARE INDIA LIMITED
CIN: L85100WB2014PLC202429
Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake,
Bidhan Nagar,Sai Complex, North 24 Parganas, Kolkata – 700106.
Web: https://www.nephrocareindia.com/
cs@nephrocareindia.com | Mobile No. 9004551166

Date: 12/11/2026

To,
The Manager - Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051

Symbol - *NEPHROCARE*

Sub: Outcome of Board Meeting dated 12th November 2026

Ref: Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30, 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") this is to inform you that the Board of Directors of the Company at its meeting duly held today Thursday, 12th November 2026, (commenced at 04:30 P.M and concluded at 05:30 P.M) through Video Conferencing and other Audio Visual Means *inter alia*, approved and adopted the following;

1) The Standalone & Consolidated Un-Audited Financial Results of the Company along with the Statement of Assets & Liabilities and Cash Flow for the quarter and half year ended 30th September 2026;
2) Limited Review Report on Financial Results for the quarter and half year ended 30th September 2026, duly issued by the statutory auditor of the Company;

OTHER MATTERS

3) Noting the Certificate of utilization of funds raised from issue proceeds till 30th September 2026, received from the Statutory Auditors of the Company.
4) Noting of Related Party Transactions entered into during the half year ended 30th September 2026.
5) Approval for Shifting the Corporate office of the Company from EFC Limited, 12th Floor, Millennium City, Tower 2, DN Block, DN-62, Salt Lake, Sector -5, Bidhan Nagar, Kolkata – 700091 to 6th Floor, LA Block, Plot No. - 1, Salt Lake Bypass, LA Block, Sector 3, Bidhannagar, Kolkata, West Bengal 700106

The said financial results will be filed with the Stock Exchange and disseminated to the Shareholders in accordance with the applicable provisions of SEBI LODR Regulations.

NEPHRO CARE INDIA LIMITED
CIN: L85100WB2014PLC202429
Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake,
Bidhan Nagar,Sai Complex, North 24 Parganas, Kolkata – 700106.
Web: https://www.nephrocareindia.com/
cs@nephrocareindia.com | Mobile No. 9004551166

The Board meeting commenced at 04:30 P.M and concluded at 05:30 P.M (IST).

The above announcements are also being made available on the website of the Company at www.nephrocareindia.com.

Thanking you,

Yours Faithfully,

For **Nephro Care India Limited**

SOUGATA SENGUPTA
Digitally signed by SOUGATA SENGUPTA
Date: 2026.11.12 17:44:42 +05'30'

Sougata Sengupta
Company Secretary
& Compliance Officer

K. K. Chanani & Associates
Chartered Accountants
An ISO 9001:2008 Certified Firm, Certificate No.: 221010128008
Head Office: 5/1 Clive Row, 3rd Floor, Room No.78, Kolkata-700001
Branches: Bangalore, Chandigarh, Guwahati, Jaipur, Mumbai, New Delhi, Patna, Raipur and Nashik.
Contact: Dial: +91 9830044507, +9133- 22130296
Email: kkca@kkca.net.

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of Nephro Care India Limited (formerly called Nephro Care India Private Limited) for the quarter ended and year to date as on 30th September 2026 under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
Nephro Care India Limited
(formerly called Nephro Care India Private Limited)
CIN: L85100WB2014PLC202429

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results ("the Statement") of **Nephro Care India Limited** ("the Company") for the quarter ended 30-09-2026 and year to date from April 1, 2026 to September 30, 2026 together with the relevant notes thereon (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation"), including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors in their meeting held on November 12, 2026, of the Company has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulation. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in

K. K. CHANANI & ASSOCIATES INDIA Chartered Accountants

Scanned with OKEN Scanner

accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Standalone Financial Results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Krishna Kumar Chanani
Partner, K K Chanani & Associates
Chartered Accountants
Membership No. 056045
FRN No. 322232E
UDIN No. 26056045YZPTWI7884

Kolkata, the 12th November, 2026

Scanned with OKEN Scanner

Nephro Care India Limited
(Formerly called Nephro Care India Private Limited)
Registered Office:-Flat No-1JC-18, 5th Floor Sec-III, Saltlake, Kolkata, Bidhan Nagar Sai Complex, North 24 Parganas,Saltlake, West Bengal, India, 700098
Telephone No +918069841500:- Email id:- pratim.sengupta@gmail.com, website:- https://www.nephrocareindia.com
CIN:L85100WB2014PLC202429
Standalone Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2026
(All amounts in ₹ lacs,unless otherwise stated)

	Quarter ended 30 September 2026 Unaudited	Quarter ended 30 June 2026 Unaudited	Quarter ended 30 September 2025 Unaudited	Half Year Ended 30 September 2026 Unaudited	Half Year ended 30 September 2025 Unaudited	Year ended 31 March 2026 Audited
Revenue from operations	3,330.12	2,918.52	2,199.24	6,248.64	3,932.63	8,873.48
Other income	4.17	22.32	57.02	26.49	62.30	154.75
Total Income	**3,334.29**	**2,940.84**	**2,256.26**	**6,275.13**	**3,994.93**	**9,028.23**
Expenses						
Changes in inventory of pharmacy, drugs and consumables	(8.18)	(76.82)	(81.61)	(85.00)	(95.39)	(106.21)
Purchases of pharmacy, drugs and consumables	937.56	975.81	592.25	1,913.37	1,118.02	2,744.03
Employee Benefit Expenses	486.71	404.06	369.23	890.77	685.77	1,483.01
Finance Cost	5.31	3.46	(1.13)	8.77	13.11	15.87
Depreciation and Amortisation	122.71	119.35	94.94	242.06	211.05	507.40
Other expenses	1,429.61	1,253.82	939.84	2,683.43	1,784.45	3,920.31
Total expenses	2,973.72	2,679.68	1,913.53	5,653.40	3,717.02	8,564.41
Profit/(loss) before tax	**360.57**	**261.16**	**342.73**	**621.73**	**277.91**	**463.82**
Tax expense						
Current tax	89.22	114.13	73.30	203.35	73.30	135.33
Tax Expenses of prior years	-	(9.21)	-	(9.21)		8.00
Deferred Tax	(4.87)	(4.55)	10.24	(9.42)	10.24	(16.41)
	84.35	**100.37**	**83.54**	**184.72**	**83.54**	**126.93**
Profit/(loss) for the period/year	**276.22**	**160.79**	**259.18**	**437.01**	**194.36**	**336.89**
Paid up equity share capital (face value Rs 10/- per share)	**1,648.64**	**1,648.64**	**1,648.64**	**1,648.64**	**1,648.64**	**1,648.64**
Reserve & Surplus						**4,036.71**
Earnings per equity share (not annualised) Basic and diluted	1.68	0.98	1.57	2.66	1.18	2.04

Note:-

1) The unaudited standalone financial results of the company for the quarter and half year ended 30 September 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on November 12, 2026. The Statutory Auditor of the company has issued unmodified opinion thereon.

2) The above financial results have been preapred in accordance with and comply in all materials with the Accouting Standards (iGAAP) prescribed under Section 133 of the Companies Act , 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of Securities and Exchange Board of India (Listing and Obligations and Disclosure Requirements) Regulations 2015, as amended

3) The compliance of IND-AS is not applicabie as company is listed on SME Platform on NSE Emerge

4) There are no exceptional items during the period under review

5) The company was listed on SME Platform on NSE Emerge on 5th July, 2024.

6) The quarter ended on 31 December 2025 is the first period, after listing on NSE Emerge on dated 05th July 2024, that company has voluntarily adopted reporting of the quarterly results.

7) Figures for the previous year have been regrouped and reclassified to conform to classification of the current period wherever necessary

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN: 03501703)

Tapas Saha
(Chief Financial Officer)
(PAN:BNSPS8900F)

Sougata Sengupta
(Company Secretary)
(M.N:-A17680)

Place: Kolkata
Date: 12th Day of November 2026

Nephro Care India Limited
(Formerly called Nephro Care India Private Limited)
CIN:L85100WB2014PLC202429
Standalone Statement of Assets and Liabilities as at 30 September 2026
(All amounts in ₹ Lakhs , unless otherwise stated)

	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
Equity and liabilities		
Shareholders' funds		
Share capital	1,648.64	1,648.64
Reserves and surplus	4,473.72	4,036.71
	6,122.36	**5,685.35**
Non-Current liabilities		
Deferred Tax Liability (net)	4.39	13.81
Long-term provisions	52.23	40.50
Other Long Term Liabilities	4.38	-
	61.00	**54.31**
Current liabilities		
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	42.98	42.96
- total outstanding dues of creditors other than micro and small enterprises	672.08	627.54
Other current liabilities	664.44	521.64
Short-term provisions	340.48	235.13
	1,719.98	**1,527.27**
Total	**7,903.34**	**7,266.93**
Assets		
Non-Current Assets		
Property,Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	3,306.40	3,401.08
(ii) Capital work-in-progress	31.97	42.56
(iii) Intangible Assets under development	20.79	10.89
Non-current investments	50.28	179.78
Long term loans and advances	325.65	169.41
Other non-current assets	686.91	394.86
	4,422.00	**4,198.58**
Current assets		
Current Investments	1,205.54	1,001.58
Inventories	313.81	228.81
Trade Receivables	835.15	604.27
Cash and cash equivalents	601.73	638.57
Short term loans and advances	0.40	3.84
Other current assets	524.71	591.28
	3,481.34	**3,068.35**
Total	**7,903.34**	**7,266.93**

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN: 03501703)

Tapas Saha
(Chief Financial Officer)
(PAN:BNSPS8900F)

Sougata Sengupta
(Company Secretary)
(M.N:-A17680)

Place: Kolkata
Date: 12th Day of November 2026

Nephro Care India Limited
(Formerly called Nephro Care India Private Limited)
CIN:L85100WB2014PLC202429

Standalone Statement of Cash Flow for the Half year ended 30 September 2026

(All amounts in ₹ Lakhs , unless otherwise stated)

		Half-year Ended 30 September 2026 Unaudited	Half-year Ended 30 September 2025 Unaudited
A. Cash flow from operating activities :			
Profit before tax		**621.73**	**277.91**
Adjustment for :			
Depreciation		242.06	211.05
Interest Income from Fixed Deposit		(5.46)	(5.32)
Sundry Balance Written Off		-	(0.01)
GST Written off		204.02	-
Profit from sale of investments		(3.96)	(42.89)
Operating profit before working capital changes		**1,058.39**	**440.74**
Adjustments for changes in working capital:			
(Increase) / decrease in assets:			
Inventories		(85.00)	(95.39)
Trade Receivables		(230.89)	(133.95)
Other current assets		(79.81)	(123.98)
Short-term loans and advances		3.44	(4.04)
Long-term loans and advances		(156.23)	142.45
Other non-current assets		(292.05)	(50.00)
Increase / (decrease) in liabilities:			
Trade Payables		44.56	121.71
Long-term provisions		11.74	-
Other current liabilities		42.79	(538.68)
Cash generated from operations		**316.94**	**(241.14)**
Income taxes paid (net of refunds)		(146.43)	(72.42)
Net cash generated from operating activities	**(A)**	**170.51**	**(313.56)**
B. Cash flow from investing activities			
Purchase of Property, Plant and Equipment		(147.38)	(438.46)
Capital work-in -progress		0.69	(41.35)
Proceeds from Fixed Deposits		150.00	244.00
Investment in Fixed Deposits		(20.00)	(158.80)
Redemption of Mutual Fund		100.00	1,642.87
Investment in Mutual Funds		(300.00)	(1,200.00)
Interest Income from Fixed Deposits		4.96	4.52
Net cash used in investing activities	**(B)**	**(211.73)**	**52.78**
C. Cash flow from financing activities			
Government Grant Received		4.38	-
Net cash used in financing activities	**(C)**	**4.38**	**-**
Net increase in cash and cash equivalents	**A+B+C)**	**(36.84)**	**(260.78)**
Cash and cash equivalents as at the beginning of the year		**638.57**	**465.83**
Cash and cash equivalents as at the end of the year		**601.73**	**205.06**
Note:			
Cash and bank balances		601.73	205.06
Less: Other bank balances			
Cash and cash equivalents		**601.73**	**205.06**

The standalone statement of cashflow has been prepared under the indirect method as set out in Accounting Standard 3 on Cash Flow Statement as specified under Section 133 of the Companies Act 2013 read with Companies (Accounting Standards) Rules, 2021

P. K. CHANANI & ASSOCIATES INDIA Chartered Accountants

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN: 03501703)

NEPHRO CARE INDIA LTD. KOL-106 JC 18 SALT LAKE

Tapas Saha
(Chief Financial Officer)
(PAN:BNSPS8900F)

Sougata Sengupta
(Company Secretary)
(M.N.:A17680)

Place: Kolkata
Date: 12th Day of November 2026

ro Care India Limited
merly called Nephro Care India Private Limited)
:L85100WB2014PLC202429
tandalone Statement of Revenue, Results, Assets and Liabilities for the Quarter and Half Year Ended 30 September 2026
All amounts in ₹ Lakhs, unless otherwise stated)

Sl. No	Particulars	Quarter ended 30 September 2026 Unaudited	Quarter ended 30 June 2026 Unaudited	Quarter ended 30 September 2025 Unaudited	Half Year Ended 30 September 2026 Unaudited	Half Year Ended 30 September 2025 Unaudited	Year ended 31 March 2026 Audited
1	**Segment Revenue [Net Sales/Income]**						
	Income from IPD Services	1,915.45	1,565.30	1,122.17	3,480.75	1,892.62	4,330.48
	Income from OPD Services	836.60	758.31	624.12	1,594.91	1,190.91	2,519.18
	Income from sale of medicines from pharmacy	578.07	594.91	465.42	1,172.98	861.57	2,036.30
		3,330.12	2,918.52	2,211.71	**6,248.64**	3,945.10	**8,885.96**
	Less: Discount	-	-	12.47	-	12.47	12.47
	Net Sale	3,330.12	2,918.52	2,199.24	6,248.64	3,932.63	**8,873.49**
	Add: Profit on Sale of Investment	-	3.96	42.89	3.96	42.89	44.47
	Add: Interest Income	2.78	5.42	5.32	8.20	5.32	10.75
	Add: Technician Charges for Dialysis	-	-	1.10	-	1.10	1.10
	Add: Dialysis machine Rental charges	-	1.32	5.94	1.32	9.20	18.32
	Add: Others	1.38	11.62	1.77	13.00	3.79	80.10
	Net Sales/Income from Operations	**3,334.29**	**2,940.84**	**2,256.25**	**6,275.13**	**3,994.93**	**9,028.23**
	Inter-Segment Sales						
	Income from sale of medicines from pharmacy	**428.68**	**329.38**	**274.93**	**758.06**	**458.66**	**906.78**
2	**Information about Segment Profits:**						
	Incomes after segment specific expenses:						
	IPD Services	1,125.22	1,006.34	886.57	2,131.56	1,421.88	3,271.18
	OPD Services	510.89	578.24	547.50	1,089.13	1,085.81	2,118.53
	Sale of medicines from pharmacy	160.03	96.93	98.28	256.96	232.29	461.84
		1,796.14	**1,681.51**	**1,532.35**	**3,477.65**	2,739.98	**5,851.55**
	Add: Other incomes	4.17	22.32	62.30	26.49	62.30	154.75
	Less: Unallocable expenses						
	Employee Benefit Expenses	486.71	404.06	369.23	890.77	685.77	1,483.00
	Finance Cost	5.31	3.46	(1.13)	8.77	13.11	15.87
	Depreciation and Amortisation	122.71	119.35	94.94	242.06	211.05	507.40
	Other expenses	825.01	915.80	788.87	1,740.81	1,614.43	3,536.21
	Profit/Loss before tax	**360.57**	**261.16**	**342.72**	**621.73**	**277.90**	**463.83**
	Less: Taxes	84.35	100.37	83.54	184.72	83.54	126.94
	Profit/Loss after tax	**276.22**	**160.79**	**259.18**	**437.01**	**194.36**	**336.89**
3	**Information about segment assets & liabilities**						
	Segment Assets:						
	IPD Services	3,418.83	3,418.99	2,469.48	3,418.83	2,469.48	3,247.03
	OPD Services	640.78	393.61	717.61	640.78	717.61	449.88
	Pharmacy	614.40	654.34	493.01	614.40	493.01	659.56
	Others	3,229.33	3,137.25	3,009.26	3,229.33	3,009.26	2,910.46
	Total Assets	**7,903.34**	**7,604.19**	**6,689.36**	**7,903.34**	**6,689.36**	**7,266.93**
	Segment Liabilities:						
	IPD Services	191.07	266.92	147.84	191.07	147.84	261.07
	OPD Services	82.19	82.67	158.57	82.19	158.57	118.98
	Pharmacy	715.06	864.31	505.26	715.06	505.26	687.21
	Others	792.66	544.16	247.75	792.66	247.75	514.32
	Total Liabilities	**1,780.98**	**1,758.06**	**1,059.42**	**1,780.98**	**1,059.42**	**1,581.58**

K.K. CHANANI & ASSOCIATES INDIA Chartered Accountants

NEPHRO CARE INDIA LTD. KOL-106 JC 18 SALT LAKE

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN 03501703)

Tapas Saha
(Chief Financial Officer)
(PAN BNSPS8900F)

Sougata Sengupta
(Company Secretary)
(M.N -A17680)

Place: Kolkata
Date: 12th Day of November 2026

K. K. Chanani & Associates
Chartered Accountants
An ISO 9001:2008 Certified Firm, Certificate No.: 221010128008
Head Office: 5/1 Clive Row, 3rd Floor, Room No.78, Kolkata-700001
Branches: Bangalore, Chandigarh, Guwahati, Jaipur, Mumbai, New Delhi, Patna, Raipur and Nashik.
Contact: Dial: +91 9830044507, +9133- 22130296
Email: kkca@kkca.net.

Independent Auditor's Review Report on the Unaudited Consolidated Financial Results of Nephro Care India Limited (formerly called Nephro Care India Private Limited) for the quarter ended and year to date as on 30th September 2026 under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
Nephro Care India Limited
(formerly called Nephro Care India Private Limited)
CIN: L85100WB2014PLC202429

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Nephro Care India Limited** (the "Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "Group") for the quarter ended 30-09-2026 and year to date from April 1, 2026 to September 30, 2026 together with the relevant notes thereon (the "Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation"), including relevant circulars issued by the SEBI from time to time.

2. This Statement is the responsibility of the Parent Company's Management and approved by the Parent's Board of Directors in their meeting held on November 12, 2026, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard "Interim Financial Reporting" (As 25) prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.

Scanned with OKEN Scanner

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for the financial and accounting matters and applying analytical and other review. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entity:

   a) **Vivacity Multiple Ventures Private Limited**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid applicable Accounting Standard and other accounting principles generally accepted in India, , has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial result in respect of one subsidiary company included in the consolidated unaudited financial results, whose interim financial information results total assets Rs 9.48 lacs as on 30 September 2026 total income Rs NIL and Rs NIL, total loss after tax Rs.0.58 lacs and Rs. 0.58 for the quarter ended September 30, 2026 and for the period from April 1, 2026 to September 30, 2026 respectively and the net cash outflows Rs 0.52 lacs for the period from April 1, 2026 to September 30, 2026 as considered in the Statement. This financial result has been reviewed by other auditor whose report has been furnished to us by the management and our conclusion on this Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditors and the procedures performed by us stated in



Scanned with OKEN Scanner

the paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matter.

Krishna Kumar Chanani
Partner, K K Chanani & Associates
Chartered Accountants
Membership No. 056045
FRN No. 322232E
UDIN No. 26056045RBDOPA5011

Kolkata, the 12th November, 2026

Scanned with OKEN Scanner

Nephro Care India Limited
(Formerly called Nephro Care India Private Limited)
Registered Office:-Flat No-1JC-18, 5th Floor Sec-III, Saltlake, Kolkata, Bidhan Nagar Sai Complex, North 24 Parganas,Saltlake, West Bengal, India, 700098
Telephone No +918069841500:- Email id:- pratim.sengupta@gmail.com, website:- https://www.nephrocareindia.com
CIN.L85400WB2014PLC202429

Consolidated Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2026
(All amounts in ₹ lacs,unless otherwise stated)

	Quarter ended September 30, 2026 Unaudited	Quarter ended June 30, 2026 Unaudited	Quarter ended September 30, 2025 Unaudited	Half Year Ended September 30, 2026 Unaudited	Half Year ended September 30, 2025 Unaudited	Year ended March 31, 2026 Audited
Revenue from operations	3,330.12	2,918.52	2,199.24	6,248.64	3,932.63	8,873.48
Other income	4.17	22.32	57.02	26.49	62.30	154.75
Total Income	**3,334.29**	**2,940.84**	**2,256.26**	**6,275.13**	**3,994.93**	**9,028.23**
Expenses						
Changes in inventory of pharmacy, drugs and consumables	(8.18)	(76.82)	(81.61)	(85.00)	(95.39)	(106.21)
Purchases of pharmacy, drugs and consumables	937.56	975.81	592.25	1,913.37	1,118.02	2,744.03
Employee Benefit Expenses	486.71	404.06	369.23	890.77	685.77	1,483.01
Finance Cost	5.31	3.46	(1.13)	8.77	13.11	15.87
Depreciation and Amortisation	122.71	119.35	94.94	242.06	211.05	507.40
Other expenses	1,430.19	1,253.82	939.84	2,684.01	1,784.45	3,920.31
Total expenses	**2,974.30**	**2,679.68**	**1,913.53**	**5,653.98**	**3,717.02**	**8,564.41**
Profit/(loss) before tax	**359.99**	**261.16**	**342.73**	**621.15**	**277.91**	**463.82**
Tax expense						
Current tax	89.22	114.13	73.30	203.35	73.30	135.33
Tax Expenses of prior years	-	(9.21)	-	(9.21)		
Deferred Tax	(4.87)	(4.55)	10.24	(9.42)	10.24	8.00 (18.41)
	84.35	**100.37**	**83.54**	**184.72**	**83.54**	**126.93**
Profit/(loss) for the period/year	**275.64**	**160.79**	**259.18**	**436.43**	**194.36**	**336.89**
Profit/(Loss) for the year-attributable to owners of the parent	275.92	160.79	259.18	436.71	194.36	336.89
Profit/(Loss) for the year -attributable to minority interest	(0.28)	-	-	(0.28)	-	-
Paid up equity share capital (face value Rs 10/- per share)	**1,648.64**	**1,648.64**	**1,648.64**	**1,648.64**	**1,648.64**	**1,648.64**
Reserve & Surplus	-	-	-	-	-	**4,036.71**
Earnings per equity share (not annualised) Basic and diluted	1.67	0.98	1.57	2.65	1.18	2.04

Note -

1) The unaudited consolidated financial results of the company for the quarter and half year ended 30 September 2026 , have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on November 12, 2026. The Statutory Auditor of the company has issued unmodified opinion thereon.

2) The above financial results have been preapred in accordance with and comply in all materials with the Accouting Standards (IGAAP) prescribed under Section 133 of the Companies Act , 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of Securities and Exchange Board of India (Listing and Obligations and Disclosure Requirements) Regulations 2015, as amended

3) The compliance of IND-AS is not applicable as company is listed on SME Platform on NSE Emerge
4) There are no exceptional items during the period under review
5) The company was listed on SME Platform on NSE Emerge on 5th July, 2024
6) The quarter ended on 31 December 2025 is the first period, after listing on NSE Emerge on dated 05th July 2024, that company has voluntarily adopted reporting of the quarterly results.

7) Figures for the previous year have been regrouped and reclassified to conform to classification of the current period wherever necessary

V. K. CHANANI & ASSOCIATES INDIA Chartered Accountants

NEPHRO CARE INDIA LTD KOL-106 JC-18 SALT LAKE

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN: 03501703)

Tapas Saha
(Chief Financial Officer)
(PAN:BNSPS8900F)

Sougata Sengupta
(Company Secretary)
(M.N:-A17680)

Place: Kolkata
Date: 12th Day of November 2026

Nephro Care India Limited
(Formerly called Nephro Care India Private Limited)
CIN:L85100WB2014PLC202429
Consolidated Statement of Assets and Liabilities as at 30 September 2026
(All amounts in ₹ Lakhs , unless otherwise stated)

	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
Equity and liabilities		
Shareholders' funds		
Share capital	1,648.64	1,648.64
Reserves and surplus	4,473.42	4,036.71
Total of equity (for shareholders of Parent)	6,122.06	5,685.35
Minority Interest	4.62	4.90
	6,126.68	**5,690.25**
Non-Current liabilities		
Deferred Tax Liability (net)	4.39	13.81
Long-term provisions	52.23	40.50
Other Long Term Liabilities	4.38	-
	61.00	**54.31**
Current liabilities		
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	42.98	42.96
- total outstanding dues of creditors other than micro and small enterprises	672.08	627.54
Other current liabilities	664.51	621.90
Short-term provisions	340.48	235.13
	1,720.05	**1,527.53**
Total	**7,907.73**	**7,272.09**
Assets		
Non-Current Assets		
Property,Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	3,306.40	3,401.08
(ii) Capital work-in-progress	31.97	42.56
(iii) Intangible Assets under development	20.79	10.89
Non-current investments	45.18	174.68
Long term loans and advances	325.65	169.41
Other non-current assets	686.91	394.86
	4,416.90	**4,193.48**
Current assets		
Current Investments	1,205.54	1,001.58
Inventories	313.81	228.81
Trade Receivables	835.16	604.27
Cash and cash equivalents	611.21	648.57
Short term loans and advances	0.40	3.84
Other current assets	524.71	591.54
	3,490.83	**3,078.61**
Total	**7,907.73**	**7,272.09**

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN: 03501703)

Sougata Sengupta
(Company Secretary)
(M.N. A17680)

Tapas Saha
(Chief Financial Officer)
(PAN:BNSPS8900F)

Place: Kolkata
Date: 12th Day of November 2026

...hro Care India Limited
...ormerly called Nephro Care India Private Limited)
CIN:L85100WB2014PLC202429
Consolidated Statement of Cash Flow for the Half year ended 30 September 2026
(All amounts in ₹ Lakhs , unless otherwise stated)

		Half-year Ended 30 September 2026 Unaudited	Half-year Ended 30 September 2025 Unaudited
A. Cash flow from operating activities :			
Profit before tax		**621.15**	**277.91**
Adjustment for :			
Depreciation		242.06	211.05
Interest Income from Fixed Deposit		(5.46)	(5.32)
Sundry Balance Written Off		-	(0.01)
GST Written off		204.02	
Profit from sale of investments		(3.96)	(42.89)
Operating profit before working capital changes		**1,057.81**	**440.74**
Adjustments for changes in working capital:			
(Increase) / decrease in assets:			
Inventories		(85.00)	(95.39)
Trade Receivables		(230.89)	(133.95)
Other current assets		(79.55)	(123.98)
Short-term loans and advances		3.44	(4.04)
Long-term loans and advances		(156.23)	142.45
Other non-current assets		(292.05)	(50.00)
Increase / (decrease) in liabilities:			
Trade Payables		44.56	121.71
Long-term provisions		11.74	-
Other current liabilities		42.59	(538.68)
Cash generated from operations		**316.42**	**(241.14)**
Income taxes paid (net of refunds)		(146.43)	(72.42)
Net cash generated from operating activities	**(A)**	**169.99**	**(313.56)**
B. Cash flow from investing activities			
Purchase of Property, Plant and Equipment		(147.38)	(438.46)
Capital work-in -progress		0.69	(41.35)
Proceeds from Fixed Deposits		150.00	244.00
Investment in Fixed Deposits		(20.00)	(158.80)
Redemption of Mutual Fund		100.00	1,642.87
Investment in Mutual Funds		(300.00)	(1,200.00)
Interest Income from Fixed Deposits		4.96	4.52
Net cash used in investing activities	**(B)**	**(211.73)**	**52.78**
C. Cash flow from financing activities			
Government Grant Received		4.38	-
Net cash used in financing activities	**(C)**	**4.38**	**-**
Net increase in cash and cash equivalents	**(A+B+C)**	**(37.36)**	**(260.78)**
Cash and cash equivalents as at the beginning of the year		**648.57**	**465.83**
Cash and cash equivalents as at the end of the period		**611.21**	**205.06**
Note:			
Cash and bank balances		611.21	205.06
Less: Other bank balances		-	-
Cash and cash equivalents		**611.21**	**205.06**

The standalone statement of cashflow has been prepared under the indirect method as set out in Accounting Standard 3 on Cash Flow Statement as specified under Section 133 of the Companies Act 2013 read with Companies (Accounting Standards) Rules, 2021

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN: 03501703)

Tapas Saha
(Chief Financial Officer)
(PAN:BNSPS8900F)

Sougata Sengupta
(Company Secretary)
(M.N:-A17680)

Place: Kolkata
Date: 12th Day of November 2026

Limited
Nephro Care India Private Limited)
2014PLC202429
unaudited Statement of Revenue, Results, Assets and Liabilities for the Quarter and Half Year Ended 30 September 2026
s in ₹ Lakhs, unless otherwise stated)

Particulars	Quarter ended 30 September 2026 Unaudited	Quarter ended 30 June 2026 Unaudited	Quarter ended 30 September 2025 Unaudited	Half Year Ended 30 September 2026 Unaudited	Half Year Ended 30 September 2025 Unaudited	Year ended 31 March 2026 Audited
1 Segment Revenue [Net Sales/Income]						
Income from IPD Services	1,915.45	1,565.30	1,122.17	3,480.75	1,892.62	4,330.48
Income from OPD Services	836.60	758.31	624.12	1,594.91	1,190.91	2,519.18
Income from sale of medicines from pharmacy	578.07	594.91	465.42	1,172.98	861.57	2,036.30
	3,330.12	**2,918.52**	**2,211.71**	**6,248.64**	**3,945.10**	**8,885.96**
Less: Discount	-	-	12.47	-	12.47	12.47
Net Sale	**3,330.12**	**2,918.52**	**2,199.24**	**6,248.64**	**3,932.63**	**8,873.49**
Add: Profit on Sale of Investment	-	3.96	42.89	3.96	42.89	44.47
Add: Interest Income	2.78	5.42	5.32	8.20	5.32	10.75
Add: Technician Charges for Dialysis	-	-	1.10	-	1.10	1.10
Add: Dialysis machine Rental charges	-	1.32	5.94	1.32	9.20	18.32
Add: Others	1.39	11.62	1.76	13.01	3.79	80.10
Net Sales/Income from Operations	**3,334.29**	**2,940.84**	**2,256.26**	**6,275.13**	**3,994.93**	**9,028.23**
Inter-Segment Sales						
Income from sale of medicines from pharmacy	**428.68**	**329.38**	**274.93**	**758.06**	**458.66**	**906.78**
2 Information about Segment Profits:						
Incomes after segment specific expenses:						
IPD Services	1,125.22	1,006.34	886.57	2,131.56	1,421.88	3,271.18
OPD Services	510.89	578.24	547.50	1,089.13	1,085.81	2,118.53
Sale of medicines from pharmacy	160.03	96.93	98.28	256.96	232.29	461.84
	1,796.14	**1,681.51**	**1,532.35**	**3,477.65**	**2,739.98**	**5,851.55**
Add: Other incomes	4.17	22.32	62.30	26.49	62.30	154.75
Less: Unallocable expenses						
Employee Benefit Expenses	486.71	404.06	369.23	890.77	685.77	1,483.01
Finance Cost	5.31	3.46	(1.13)	8.77	13.11	15.87
Depreciation and Amortisation	122.71	119.35	94.94	242.06	211.05	507.40
Other expenses	825.59	915.80	788.88	1,741.39	1,614.44	3,536.21
Profit/Loss before tax	**359.99**	**261.16**	**342.73**	**621.15**	**277.91**	**463.82**
Less: Taxes	84.35	100.37	83.54	184.72	83.54	126.93
Profit/Loss after tax	**275.64**	**160.79**	**259.18**	**436.43**	**194.36**	**336.89**
3 Information about segment assets & liabilities						
Segment Assets:						
IPD Services	3,418.83	3,418.99	2,469.48	3,418.83	2,469.48	3,247.03
OPD Services	640.78	393.61	717.61	640.78	717.61	449.88
Pharmacy	614.40	654.34	493.01	614.40	493.01	659.56
Others	3,233.72	3,147.53	3,009.26	3,233.72	3,009.26	2,915.62
Total Assets	**7,907.73**	**7,614.47**	**6,689.36**	**7,907.73**	**6,689.36**	**7,272.09**
Segment Liabilities:						
IPD Services	191.07	266.92	147.84	191.07	147.84	261.07
OPD Services	82.19	82.67	158.57	82.19	158.57	118.98
Pharmacy	715.06	864.31	505.26	715.06	505.26	687.21
Others	792.73	544.44	247.75	792.73	247.75	514.32
Total Liabilities	**1,781.05**	**1,758.34**	**1,059.42**	**1,781.05**	**1,059.42**	**1,581.58**

V. K. CHANANI & ASSOCIATES * INDIA * Chartered Accountants

NEPHRO CARE INDIA LTD * KOL-106 * JC 18 SALT LAKE

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN: 03501103)

Tapas Saha
(Chief Financial Officer)
(PAN:BNSPS8900F)

Sougata Sengupta
(Company Secretary)
(M.N.-A17680)

Place: Kolkata
Date: 12th Day of November 2026

Nephro Care India Limited
Related Parties Details as on 30th September 2026
(All amounts in INR)

Name	PAN No	Nature of Expenses	Relationship with Listed Entity	Opening Balance as on 01-04-2026	Value of Transaction from 01-04-26 to 30-09-26	Outstanding as on 30-09-26	Payable/ Receivable
Pratim Sengupta	BJYPS7583N	Consultancy Charges	Managing Director	1,126,165.00	43,177,812.00	8,639,536.00	Payable
Sutapa Sen	CMOPS6554D	Consultancy Charges	Director	0.00	258,872.00	-	-
Pritam Sengupta	DFNPS3052B	Consultancy Charges	Director	0.00	66,488.00	-	
Tapas Saha	BNSPS8900F	Salaries and Bonus	Chief Financial Officer	200,000.00	1,600,000.00	300,000.00	Payable
Sougata Sengupta	ASJPS3532L	Salaries and Bonus	Company Secretary	100,000.00	600,000.00	100,000.00	Payable
Sampurna Women Care and IFV	CMOPS6554D	Revenue from Operations	Enterprise having significant influence	2,832,722.00	1,342,020.00	2,528,907.00	Receivable
Arica Diagnostic Private Limited	AAICA6734A	Blood Consumables	Enterprise having significant influence	770,300.00	2,166,828.00	1,040,416.00	Payable
Debasish Ghoshal	SEWPG3140P	Directors' Sitting Fees	Director	0.00	40,000.00	-	-
Sandeep Ghate	AACPG0447M	Directors' Sitting Fees	Director	0.00	50,000.00	-	-
Alo Sengupta	AJFPS5226G	Directors' Sitting Fees	Director	0.00	40,000.00	-	-
Sudip Barman	AFWPB7794M	Directors' Sitting Fees	Director	0.00	50,000.00	-	-

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Managing Director
(DIN: 03501703)

NEPHRO CARE INDIA LTD. KOL-106 JC 18 SALT LAKE

K. K. Chanani & Associates
Chartered Accountants
An ISO 9001:2008 Certified Firm, Certificate No.: 221010128008
Head Office: 5/1 Clive Row, 3rd Floor, Room No.78, Kolkata-700001
Branches: Bangalore, Chandigarh, Guwahati, Jaipur, Mumbai, New Delhi, Patna, Raipur and Nashik.
Contact: Dial: +91 9830044507, +9133- 22130296
Email: kkca@kkca.net.

To,
The Board of Directors,
Nephro Care India Limited,
(Formerly called Nephro Care India Private Limited)
Flat No -1JC-18 , 5th Floor Sec-III
Salt Lake , Bidhan Nagar Sai Complex
North 24 Paraganas
Kolkata-700098, India

Sub: Certificate on utilization of fund raised through IPO

On the basis of verification and examination of the books of **"Nephro Care India Ltd"** (" the Company") and as per the information and explanations provided to us, by the Company, we hereby certify that the Company had fully utilized the amount till 30th September 2026, for the purpose of the objects as stated in the Prospectus

(Rs in lacs)

Sr No	Objects as disclosed in the Offer document	Amount disclosed in the offer document	Actual utilised Amount till 30-09-2026	Unutilised Amount	Remarks
1	Setting up a Multi-Speciality Hospital in the name of Vivacity Multi Specialty Hospital (unit of Nephro Care) at Kolkata (Madhyamgaram), West Bengal	2,615.34	2,615.34	-	-
2	General Corporate Purposes	1,002.70	1,002.70	-	-

Scanned with OKEN Scanner

This certificate is issued solely at the request of the company for the purpose of submission on National Stock Exchange of India (NSE Emerge Platform). This certificate should not be used for any purpose other than intended purpose without our prior written consent. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.

Krishna Kumar Chanani
Partner, K K Chanani & Associates
Chartered Accountants
Membership No. 056045
FRN No. 322232E
UDIN No: **26056045CRWOHN9313**

Kolkata, the 12th November, 2026

Scanned with OKEN Scanner